drugset
drugset / Trial / NCT00616551

Efficacy and Safety of C2L-OCT-01 PR in Acromegalic Patients

NCT00616551 ↗

Phase 3 Completed 65 enrolled Ambrilia Biopharma, Inc.
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the biological safety and efficacy of using the drug, C2L-OCT-01 PR, 30 mg to treat acromegalic patients.

Timeline

Start
2007-04
Primary completion
2008-02
Completion
2008-02

Drugs

EvaluationDrugModalityDoseRoute
Subject C2L-OCT-01 PR Unknown 30 mg Intramuscular
Comparator Octreotide Peptide 30 mg Intramuscular

Indications

acromegaly